Development and Screening of a Series of Antibody‐Conjugated and Silica‐Coated Iron Oxide Nanoparticles for Targeting the Prostate‐Specific Membrane Antigen

No abstract is available for this paper.

• Publication year

  2014

• Venue

  ChemMedChem

• Publication date

  2014-07-01

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1002/cmdc.201300549PMID 24591351PMCID PMC4082462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current progress on aptamer-targeted oligonucleotide therapeutics.

  2013cited by this paper
• PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

  2013cited by this paper
• New iron-oxide particles for magnetic nanoparticle hyperthermia: an in-vitro and in-vivo pilot study

  2013cited by this paper
• Effect of ligand density, receptor density, and nanoparticle size on cell targeting.

  2013cited by this paper
• Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.

  2013cited by this paper
• Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy.

  2011cited by this paper
• Surface engineering of iron oxide nanoparticles for targeted cancer therapy.

  2011cited by this paper
• Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy

  2011cited by this paper
• Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.

  2011cited by this paper
• Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.

  2011cited by this paper
• Criteria impacting the cellular uptake of nanoparticles: a study emphasizing polymer type and surfactant effects.

  2011cited by this paper
• Effects of Polyethylene Glycol Spacer Length and Ligand Density on Folate Receptor Targeting of Liposomal Doxorubicin In Vitro

  2010cited by this paper
• Design considerations for tumour-targeted nanoparticles.

  2010cited by this paper
• Targeted therapies for prostate cancer against the prostate specific membrane antigen.

  2009cited by this paper
• Multifunctional nanoparticles for prostate cancer therapy

  2009cited by this paper
• Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy

  2008cited by this paper
• Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors

  2007cited by this paper
• Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.

  2007cited by this paper
• Technology Insight: monoclonal antibody imaging of prostate cancer

  2006cited by this paper
• Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications.

  2005cited by this paper
• Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy

  2005cited by this paper
• Overview of prostate-specific membrane antigen.

  2004cited by this paper
• The relative impact and future burden of prostate cancer in the United States.

  2004cited by this paper
• Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

  1999cited by this paper
• Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

  1997cited by this paper
• Synthesis of Nanosized Gold−Silica Core−Shell Particles

  1996cited by this paper

• A Review On “The Role of Nanomaterials in Advancing Sustainable Engineering”

  2024cites this paper
• Nanomedicine in cancer therapy

  2023cites this paper
• Nanotechnological strategies for prostate cancer imaging and diagnosis

  2022cites this paper
• All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation.

  2021cites this paper
• Functionalized nano-targeted moieties in management of prostate cancer.

  2020cites this paper
• Silica‐Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment

  2020cites this paper
• Correlation between physicochemical properties of superparamagnetic iron oxide nanoparticles and their reactivity with hydrogen peroxide

  2020cites this paper
• Current Good Manufacturing Practices (cGMPs) in the Commercial Development of Nanomaterials for Hyperthermia Applications

  2019cites this paper
• Actively targeted nanocarriers for drug delivery to cancer cells

  2019cites this paper
• PSMA-Targeted Mesoporous Silica Nanoparticles for Selective Intracellular Delivery of Docetaxel in Prostate Cancer Cells

  2019cites this paper
• Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.

  2019cites this paper
• Focal Treatment in Prostate Cancer With Anti-PSMA Labelled Mesoporous Silica Nanoparticles

  2019cites this paper
• Novel gadopentetic acid-doped silica nanoparticles conjugated with YPSMA-1 targeting prostate cancer for MR imaging: an in vitro study.

  2018cites this paper
• Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.

  2018cites this paper
• Nanotechnology in Urology: History of Development and Applications in Urology

  2018cites this paper
• Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.

  2016cites this paper
• (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy

  2016cites this paper
• Boronic acid recognition based-gold nanoparticle-labeling strategy for the assay of sialic acid expression on cancer cell surface by inductively coupled plasma mass spectrometry.

  2016cites this paper
• Magnetic‐Nanoparticle‐Based Immunoassays‐on‐Chip: Materials Synthesis, Surface Functionalization, and Cancer Cell Screening

  2016cites this paper
• Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.

  2016cites this paper
• Inorganic nanoparticles for biomedicine: where materials scientists meet medical research

  2016cites this paper
• Development and Application of a Novel Model System to Study “Active” and “Passive” Tumor Targeting

  2016cites this paper
• Cancer immunotherapy via nucleic acid aptamers.

  2015cites this paper
• The Application of Nanotechnology to Drug Delivery in Medicine

  2015cites this paper